journal article·2024-12-31Open access

Dodecafluoropentane emulsion as an oxygen therapeutic

Jennifer L. H. Johnson, Evan Unger

Abstract

Dodecafluoropentane emulsion (DDFPe) is a fluorocarbon (FC) under clinical development as an oxygen therapeutic and is regulated as a blood substitute. Compared to all the prior FCs studied, DDFP is the most advantageous for oxygen delivery and it is active at a lower concentration (1/200th to 1/1000th the weight of other FCs). DDFP has a boiling point of 29 °C, is more water soluble than prior FCs, and following IV administration clears via exhalation. Prior FCs had boiling points ≥ 140 °C and were retained long-term in the body causing adverse events. DDFP is a gas at biological temperature while prior FCs were liquids. Gases deliver roughly 1000 times more oxygen than liquids. DDFPe has two mechanisms of action: (1) The size of the molecule is the smallest that is a liquid at room temperature; on a molar volume basis this equates to more dissolution of oxygen. (2) Because of its boiling point close to physiologic temperature, DDFP delivers oxygen more effectively than liquid FCs.Highlight PointsFluorocarbons (FCs) dissolve oxygen and other respirable gases.FC emulsions generally do not have biological effects of and by themselves, but rather they increase the oxygen carrying capacity of the blood.There are a variety of FCs that were developed in the past as blood substitutes but they all caused accumulation in humans leading to toxic responses.Dodecafluoropentane emulsion (DDFPe) is being developed as an oxygen therapeutic to increase the oxygen carrying capacity of the blood and oxygen delivery to tissues.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hemoglobin structure and function · Traumatic Brain Injury and Neurovascular Disturbances · Cardiovascular and Diving-Related Complications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NuvOx Pharma, Tucson, AZ, USA

References (68)

Show source-provided references
1. 10.1186/s40635-023-00518-210.1186/s40635-023-00518-2 ↗
2. FDA. Criteria for safety and efficacy evaluation of oxygen therapeutics as red blood cell substitutes. FDA Guid. 2004;1–19.
3. 10.1007/978-3-319-45345-3_2610.1007/978-3-319-45345-3_26 ↗
4. 10.1161/STROKEAHA.106.46729010.1161/STROKEAHA.106.467290 ↗
5. 10.1111/j.1525-1594.2011.01418.x10.1111/j.1525-1594.2011.01418.x ↗
6. 10.1182/bloodadvances.202200797710.1182/bloodadvances.2022007977 ↗
7. 10.1080/1073119090304319210.1080/10731190903043192 ↗
8. 10.1080/21691401.2019.157788210.1080/21691401.2019.1577882 ↗
9. 10.15190/d.2020.110.15190/d.2020.1 ↗
10. 10.1081/bio-20004665910.1081/bio-200046659 ↗
11. 10.2741/327210.2741/3272 ↗
12. 10.1016/j.cis.2022.10263410.1016/j.cis.2022.102634 ↗
13. 10.1007/s00424-020-02482-210.1007/s00424-020-02482-2 ↗
14. 10.1016/s0301-5629(98)00033-710.1016/s0301-5629(98)00033-7 ↗
15. 10.1016/s0301-5629(98)00034-910.1016/s0301-5629(98)00034-9 ↗
16. 10.1016/s0301-5629(00)00363-x10.1016/s0301-5629(00)00363-x ↗
17. 10.3109/1073119940913880110.3109/10731199409138801 ↗
18. 10.1152/jappl.1995.79.4.137910.1152/jappl.1995.79.4.1379 ↗
19. Van Liew HD Burkard ME Lundgren CE et al. Method for enhancing transport of gases to tissues. United States patent US-6127428-A. published 2000-10-03.
20. 10.1201/978020350328710.1201/9780203503287 ↗
21. 10.1016/j.ultrasmedbio.2009.04.01010.1016/j.ultrasmedbio.2009.04.010 ↗
22. 10.1016/s0894-7317(97)80028-410.1016/s0894-7317(97)80028-4 ↗
23. 10.1002/clc.496020130510.1002/clc.4960201305 ↗
24. Quay SC. Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents. Europe Patent EP 1 038 535 A2. published 2000-09-27.
25. 10.1137/014301810.1137/0143018 ↗
26. 10.1016/S0021-9258(18)67112-110.1016/S0021-9258(18)67112-1 ↗
27. 10.1080/21691401.2021.187910310.1080/21691401.2021.1879103 ↗
28. 10.1080/1073119060076927110.1080/10731190600769271 ↗
29. Lundgren C, Tyssebotn I. Development of a minimal-bulk oxygen delivery product to enhance survival during hemorrhagic shock/studies regarding the use of perfluorocarbon-derived instravascular microbubbles for oxygen transport. Defense Technical Information Center; 2009.
30. 10.1179/016164105X1567710.1179/016164105X15677 ↗
31. 10.1016/j.mri.2014.10.01210.1016/j.mri.2014.10.012 ↗
32. 10.3109/1073119100363467910.3109/10731191003634679 ↗
33. 10.1166/jbn.2015.190310.1166/jbn.2015.1903 ↗
34. 10.2147/IJN.S14046210.2147/IJN.S140462 ↗
35. Koch CJ, Oprysko PR, Shuman AL, et al. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res. 2002;62(13):3626–3629.
36. 10.1093/neuonc/noz175.06110.1093/neuonc/noz175.061 ↗
37. 10.1158/2767-9764.CRC-22-043310.1158/2767-9764.CRC-22-0433 ↗
38. 10.1259/0007-1285-26-312-63810.1259/0007-1285-26-312-638 ↗
39. 10.2174/1874205X0140801002710.2174/1874205X01408010027 ↗
40. 10.1007/s12035-015-9243-x10.1007/s12035-015-9243-x ↗
41. 10.1016/j.jvir.2019.04.02010.1016/j.jvir.2019.04.020 ↗
42. 10.1161/CIRCULATIONAHA.117.02892010.1161/CIRCULATIONAHA.117.028920 ↗
43. 10.1161/01.STR.28.11.210910.1161/01.STR.28.11.2109 ↗
44. 10.1007/s12975-018-0679-y10.1007/s12975-018-0679-y ↗
45. 10.1177/109980041038450010.1177/1099800410384500 ↗
46. 10.1016/j.brainres.2016.01.01210.1016/j.brainres.2016.01.012 ↗
47. 10.1007/s10557-014-6557-210.1007/s10557-014-6557-2 ↗
48. Pharmaceuticals S. SON-3600-1001: evaluation of the safety tolerance pharmacokinetics and ultrasound contrast enhancement of qw3600 injection when administered intravenously to adult male volunteers. 1.29 - 21.31 (FDA submission: NDA 20-737).
49. Pharmaceuticals S. SON-3600-1004: evaluation of the safety and tolerance pharmacokinetics and efficacy of EchoGen® emulsion when administered intravenously to adult male subjects in conjunction with stress echocardiography. 1.32 - 31.35 (FDA submission: NDA 20-737).
50. Pharmaceuticals S. SON-3600-1004A: evaluation of the safety and tolerance pharmacokinetics and efficacy of 2% EchoGen® emulsion when administered intravenously to adult male subjects in conjunction with echocardiography. 1.36 - 31.38 (FDA submission: NDA 20-737). 1998.
51. Pharmaceuticals S. SON-3600-1002: multicenter safety pharmacokinetic and efficacy evaluation of EchoGen® emulsion as a contrast enhancing agent for use in conjunction with echocardiography in adult patients. 1.42 - 41.52 (FDA submission: NDA 20-737).
52. Pharmaceuticals S. ; SON-3600-1009: multicenter safety efficacy and pharmacokinetic evaluation of EchoGen® (2% dodecafluoropentane emulsion) as a contrast enhancing agent for use in conjunction with echocardiography in adult patients. 1.57 - 51.61 (FDA submission: NDA 20-737). 2000.
53. Pharmaceuticals S. Pharmacokinetics distribution and excretion of 14C-Iabeled PEG telomer B in EchoGen® emulsion following a single intravenous administration in the rat (FDA Submission: NDA 20-737). 1997.
54. 10.1016/0360-3016(92)90986-r10.1016/0360-3016(92)90986-r ↗
55. 10.1161/01.str.12.5.55810.1161/01.str.12.5.558 ↗
56. 10.1161/01.str.15.5.82910.1161/01.str.15.5.829 ↗
57. 10.1161/01.str.17.5.97610.1161/01.str.17.5.976 ↗
58. 10.1258/000714299190225910.1258/0007142991902259 ↗
59. 10.1097/shk.000000000000106310.1097/shk.0000000000001063 ↗
60. Rhodes CE, Denault D, Varacallo M. Physiology, oxygen transport. StatPearls Publishing (Internet); 2023.
61. 10.1152/advan.00012.200710.1152/advan.00012.2007 ↗
62. 10.1007/978-3-319-96445-4_1310.1007/978-3-319-96445-4_13 ↗
63. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
64. 10.1111/j.1745-7254.2005.00068.x10.1111/j.1745-7254.2005.00068.x ↗
65. 10.1016/j.jvir.2011.10.00110.1016/j.jvir.2011.10.001 ↗
66. 10.1007/s12035-013-8495-610.1007/s12035-013-8495-6 ↗
67. 10.1007/s12035-016-0019-810.1007/s12035-016-0019-8 ↗
68. 10.3390/medsci804004110.3390/medsci8040041 ↗